Below are the most recent publications written about "Avoidance Learning" by people in Profiles.
-
Schindler AG, Terry GE, Wolden-Hanson T, Cline M, Park M, Lee J, Yagi M, Meabon JS, Peskind ER, Raskind MM, Phillips PEM, Cook DG. Repetitive Blast Promotes Chronic Aversion to Neutral Cues Encountered in the Peri-Blast Environment. J Neurotrauma. 2021 04 01; 38(7):940-948.
-
Kelly MM, DeBeer BB, Meyer EC, Kimbrel NA, Gulliver SB, Morissette SB. Experiential avoidance as a mediator of the association between posttraumatic stress disorder symptoms and social support: A longitudinal analysis. Psychol Trauma. 2019 Mar; 11(3):353-359.
-
Lemos JC, Wanat MJ, Smith JS, Reyes BA, Hollon NG, Van Bockstaele EJ, Chavkin C, Phillips PE. Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. Nature. 2012 Oct 18; 490(7420):402-6.
-
Carvalho AF, Van Bockstaele EJ. Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion. Neurosci Lett. 2011 Aug 1; 500(1):82-5.
-
Carr ZJ, Torjman MC, Manu K, Dy G, Goldberg ME. Spatial memory using active allothetic place avoidance in adult rats after isoflurane anesthesia: a potential model for postoperative cognitive dysfunction. J Neurosurg Anesthesiol. 2011 Apr; 23(2):138-45.
-
Sions JM, Hicks GE. Fear-avoidance beliefs are associated with disability in older American adults with low back pain. Phys Ther. 2011 Apr; 91(4):525-34.
-
Carvalho AF, Reyes AR, Sterling RC, Unterwald E, Van Bockstaele EJ. Contribution of limbic norepinephrine to cannabinoid-induced aversion. Psychopharmacology (Berl). 2010 Sep; 211(4):479-91.
-
Goodkind JR, Lanoue MD, Milford J. Adaptation and implementation of cognitive behavioral intervention for trauma in schools with American Indian youth. J Clin Child Adolesc Psychol. 2010; 39(6):858-72.
-
Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. J Pharmacol Exp Ther. 2010 Jan; 332(1):190-201.
-
Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology. 2010 Jan; 58(1):69-77.